About
Technology
Issues
FAQ
Search
Profile
Top Authors
Prolific Authors
Top Journals
Main Disciplines
Main Topics
Most Cited Articles
Scientometrics
Avg Impact Factor
★★
Articles
★★★
Articles
Citing Bodies
Top Citing Authors
Top Citing Institutions
Top Citing Schools
Top Citing Journals
Top Citing Disciplines
exaly
›
Schools
›
Department of Medical Oncology
›
top-articles
Department of Medical Oncology
63
(top 2%)
papers
2.9K
(top 1%)
citations
29
(top 1%)
h
-index
55
(top 1%)
g
-index
68
all documents
3.1K
doc citations
914
citing journals
Top Articles
#
Title
Journal
Year
Citations
1
The 70-gene prognosis-signature predicts disease outcome in breast cancer patients with 1–3 positive lymph nodes in an independent validation study
Breast Cancer Research and Treatment
2009
260
2
Characterization of male breast cancer: results of the EORTC 10085/TBCRC/BIG/NABCG International Male Breast Cancer Program
Annals of Oncology
2018
246
3
Safety of pregnancy following breast cancer diagnosis: A meta-analysis of 14 studies
European Journal of Cancer
2011
227
4
Long-term toxic effects of adjuvant chemotherapy in breast cancer
Annals of Oncology
2011
221
5
HER2 and TOP2A as predictive markers for anthracycline-containing chemotherapy regimens as adjuvant treatment of breast cancer: a meta-analysis of individual patient data
Lancet Oncology, The
2011
165
6
Facts and Controversies in Systemic Treatment of Metastatic Breast Cancer
Oncologist
2004
152
7
Second and subsequent lines of chemotherapy for metastatic breast cancer: what did we learn in the last two decades?
Annals of Oncology
2002
128
8
A Phase II Study of Abemaciclib in Patients with Brain Metastases Secondary to Hormone Receptor–Positive Breast Cancer
Clinical Cancer Research
2020
102
9
Novel therapeutic strategies targeting the epidermal growth factor receptor (EGFR) family and its downstream effectors in breast cancer
Annals of Oncology
2003
97
10
Taxanes: optimizing adjuvant chemotherapy for early-stage breast cancer
Nature Reviews Clinical Oncology
2010
97
11
Locally recurrent or metastatic breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
Annals of Oncology
2010
95
12
Proliferation: the Most Prominent Predictor of Clinical Outcome in Breast Cancer
Cell Cycle
2006
76
13
Treatment of cancer during pregnancy with monoclonal antibodies: a real challenge
Expert Review of Clinical Immunology
2010
74
14
Uncovering the genomic heterogeneity of multifocal breast cancer
Journal of Pathology
2015
72
15
New therapies for ovarian cancer: Cytotoxics and molecularly targeted agents
Critical Reviews in Oncology/Hematology
2008
69
16
Locally recurrent or metastatic breast cancer: ESMO Clinical Recommendations for diagnosis, treatment and follow-up
Annals of Oncology
2009
69
17
Monoclonal Antibody-Based Targeted Therapy in Breast Cancer
Drugs
2006
62
18
Stemming Resistance to HER-2 Targeted Therapy
Journal of Mammary Gland Biology and Neoplasia
2009
57
19
Treatment of breast cancer during pregnancy: Regimen selection, pregnancy monitoring and more …
Breast
2011
57
20
Cognitive function in postmenopausal breast cancer patients one year after completing adjuvant endocrine therapy with letrozole and/or tamoxifen in the BIG 1-98 trial
Breast Cancer Research and Treatment
2011
55
21
Prediction of lymph node involvement in breast cancer from primary tumor tissue using gene expression profiling and miRNAs
Breast Cancer Research and Treatment
2011
45
22
Motherhood after breast cancer: searching for la dolce vita
Expert Review of Anticancer Therapy
2011
41
23
Targeting the Ubiquitin—Proteasome Pathway in Breast Cancer
Clinical Breast Cancer
2004
40
24
The use of gene-expression profiling to better understand the clinical heterogeneity of estrogen receptor positive breast cancers and tamoxifen response
Critical Reviews in Oncology/Hematology
2007
39
25
Quantitation of HER2 Expression or HER2:HER2 Dimers and Differential Survival in a Cohort of Metastatic Breast Cancer Patients Carefully Selected for Trastuzumab Treatment Primarily by FISH
Diagnostic Molecular Pathology
2009
38
26
Topoisomerase II alpha as a marker predicting the efficacy of anthracyclines in breast cancer: are we at the end of the beginning?
Clinical Breast Cancer
2003
37
27
Targeting mTOR in cancer: renal cell is just a beginning
Targeted Oncology
2010
35
28
Benefit to neoadjuvant anti-human epidermal growth factor receptor 2 (HER2)-targeted therapies in HER2-positive primary breast cancer is independent of phosphatase and tensin homolog deleted from chromosome 10 (PTEN) status
Annals of Oncology
2015
35
29
Microarray technology and its effect on breast cancer (re)classification and prediction of outcome
Breast Cancer Research
2003
34
30
Correlation between complete response to anthracycline-based chemotherapy and topoisomerase II-α gene amplification and protein overexpression in locally advanced/metastatic breast cancer
International Journal of Oncology
2004
30
31
Correlation between complete response to anthracycline-based chemotherapy and topoisomerase II-alpha gene amplification and protein overexpression in locally advanced/metastatic breast cancer
International Journal of Oncology
2004
29
32
Micrometastatic disease in breast cancer: Clinical implications
European Journal of Cancer
2008
27
33
Development and Validation of Gene Expression Profile Signatures in Early-Stage Breast Cancer
Cancer Investigation
2009
23
34
Frequent incidence of
BARD1
‐truncating mutations in germline
DNA
from triple‐negative breast cancer patients
Clinical Genetics
2016
23
35
Use and abuse of taxanes in the management of metastatic breast cancer
European Journal of Cancer
2003
22
36
Inconsistent Criteria Used in American Society of Clinical Oncology 2007 Update of Recommendations for the Use of Tumor Markers in Breast Cancer
Journal of Clinical Oncology
2008
21
37
Topoisomerase IIα as a Marker Predicting the Efficacy of Anthracyclines in Breast Cancer: Are We at the End of the Beginning?
Clinical Breast Cancer
2003
19
38
Subjective cognitive complaints one year after ceasing adjuvant endocrine treatment for early-stage breast cancer
British Journal of Cancer
2012
17
39
Neurological complications induced by immune checkpoint inhibitors: a comprehensive descriptive case-series unravelling high risk of long-term sequelae
Brain Communications
2021
16
40
New data on chemotherapy in the adjuvant setting
Breast
2003
15
41
Breast cancer gene expression profiling: clinical trial and practice implications
Pharmacogenomics
2005
14
42
Simultaneous targeting of estrogen receptor and HER2 in breast cancer
Expert Review of Anticancer Therapy
2010
14
43
Sowing the Soil for Cure? Results of the ABCSG-12 Trial Open a New Chapter in the Evolving Adjuvant Bisphosphonate Story in Early Breast Cancer
Journal of Clinical Oncology
2009
12
44
The best use of chemotherapy in the adjuvant setting
Breast
2003
11
45
First-Line Treatment of Metastatic Breast Cancer
American Journal of Cancer
2006
11
46
Intrathecal Trastuzumab Treatment of the Neoplastic Meningitis due to Breast Cancer: A Case Report and Review of the Literature
Case Reports in Oncological Medicine
2013
11
47
Controversies in Oncology: Surgery of the primary tumour in patients presenting with de novo metastatic breast cancer: to do or not to do?
ESMO Open
2018
10
48
Optimizing Anthracycline Therapy for Node Positive Breast Cancer
American Journal of Cancer
2002
7
49
Novel therapeutics in breast cancer—Looking to the future
Update on Cancer Therapeutics
2009
7
50
ecancermedicalscience
Ecancermedicalscience
2011
6
site/software ©
exaly
; All materials licenced under
CC by-SA
.